TScan Therapeutics, Inc. (TCRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2025 Annual Meeting of Stockholders held by TScan Therapeutics, Inc. on June 30, 2025. The filing details the voting results for the election of directors and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Two proposals were submitted to stockholders:
- Proposal 1: Election of Class I Directors
- Stephen Biggar, M.D., Ph.D.: Elected with 31,050,072 votes for.
- Gavin MacBeath, Ph.D.: Elected with 31,204,939 votes for.
- Garry Nicholson: Elected with 25,650,072 votes for.
- All three directors were elected to serve three-year terms ending in 2028.
- Proposal 2: Ratification of Independent Auditor
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Votes For: 45,724,929
- Votes Against: 64,187
- Abstain: 35,765
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The report is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Confirm the specific term end dates for the newly elected Class I directors (2028).
- Review the Definitive Proxy Statement on Schedule 14A (filed May 14, 2025) for detailed biographies of the elected directors and the rationale for the auditor selection.
- Note the significant number of broker non-votes (14,313,890) recorded for the director elections.